Last updated on September 2018

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Brief description of study

This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with recurrence after prior chemotherapy.

Clinical Study Identifier: NCT03608618

Contact Investigators or Research Sites near you

Start Over

Christina Annunziata, MD, PhD

National Cancer Institute, National Institutes of Health
Rockville, MD United States
  Connect »

Premal Thaker, MD

Washington University at St. Louis
Saint Louis, MO United States
  Connect »